What would cause the FDA to require post-marketing studies or clinical trials at the time of approval or afterwards for a new product?

What would cause the FDA to require post-marketing studies or clinical trials at the time of approval or afterwards for a new product?

• A. If the FDA becomes aware of new safety information from SADR reporting
• B. If the product is highly profitable
• C. If the company requests
• D. If market demand changes

Answer: (A)

Post-marketing studies or trials are required when new safety information arises after a product is on the market. The FDA monitors reports of adverse events, including serious adverse drug reactions, from healthcare professionals, patients, and sponsors (SADR reporting). When this new safety information comes to light, the agency may mandate post-marketing studies to better characterize risks, measure how often they occur, assess safety in specific subgroups, or evaluate long-term effects in a real-world setting. These requirements are driven by protecting patients, not by profitability, a company’s request, or changing market demand.

Post-marketing studies or trials are required when new safety information arises after a product is on the market. The FDA monitors reports of adverse events, including serious adverse drug reactions, from healthcare professionals, patients, and sponsors (SADR reporting). When this new safety information comes to light, the agency may mandate post-marketing studies to better characterize risks, measure how often they occur, assess safety in specific subgroups, or evaluate long-term effects in a real-world setting. These requirements are driven by protecting patients, not by profitability, a company’s request, or changing market demand.